Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.15 USD
Change Today -0.32 / -1.02%
Volume 134.4K
ADRO On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

aduro biotech inc (ADRO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $49.25
52 Week Low
04/30/15 - $24.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADURO BIOTECH INC (ADRO)

Related News

No related news articles were found.

aduro biotech inc (ADRO) Related Businessweek News

No Related Businessweek News Found

aduro biotech inc (ADRO) Details

Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company’s cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

50 Employees
Last Reported Date: 04/15/15
Founded in 2000

aduro biotech inc (ADRO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $886.6K
Chief Operating Officer
Total Annual Compensation: $585.9K
Chief Scientific Officer
Total Annual Compensation: $584.9K
Compensation as of Fiscal Year 2014.

aduro biotech inc (ADRO) Key Developments

Aduro BioTech, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 09:20 AM

Aduro BioTech, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 09:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Stephen T. Isaacs, Chairman, Chief Executive Officer and President.

Aduro BioTech, Inc. Adopts Amended and Restated Bylaws

Effective as of April 20, 2015, Aduro BioTech, Inc. adopted amended and restated bylaws in connection with the closing of the company’s initial public offering of shares of its common stock. The company’s board of directors and stockholders previously approved the restated Bylaws effective as of and contingent upon the closing of the company’s initial public offering.

Aduro BioTech, Inc.(NasdaqGS:ADRO) added to NASDAQ Composite Index

Aduro BioTech, Inc. has been added to Nasdaq Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADRO:US $31.15 USD -0.32

ADRO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $23.16 USD +0.18
Dynavax Technologies Corp $21.74 USD -0.24
Inovio Pharmaceuticals Inc $8.83 USD +0.57
Novavax Inc $8.87 USD +0.01
ZIOPHARM Oncology Inc $9.47 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation ADRO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 258.8x
Price/Book 20.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 130.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADURO BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at